Mallinckrodt (NYSE:MNK) received a $20.00 target price from equities researchers at SunTrust Banks in a report issued on Tuesday, Stock Target Advisor reports. The firm currently has a “hold” rating on the stock. SunTrust Banks’ target price would suggest a potential upside of 31.49% from the stock’s current price. SunTrust Banks also issued estimates for Mallinckrodt’s Q2 2019 earnings at $2.06 EPS, Q4 2019 earnings at $2.13 EPS and FY2020 earnings at $7.59 EPS.

Several other analysts also recently commented on MNK. ValuEngine downgraded shares of Mallinckrodt from a “sell” rating to a “strong sell” rating in a research report on Monday. Mizuho raised their price objective on shares of Mallinckrodt to $26.00 and gave the stock a “neutral” rating in a research report on Thursday, February 28th. Morgan Stanley set a $32.00 price objective on shares of Mallinckrodt and gave the stock a “hold” rating in a research report on Thursday, February 28th. Finally, Canaccord Genuity set a $40.00 price objective on shares of Mallinckrodt and gave the stock a “buy” rating in a research report on Monday, March 18th. Four analysts have rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Mallinckrodt currently has an average rating of “Hold” and a consensus target price of $30.69.

Shares of MNK stock opened at $15.21 on Tuesday. The company has a market cap of $1.27 billion, a PE ratio of 1.90, a P/E/G ratio of 0.15 and a beta of 2.12. Mallinckrodt has a 52 week low of $13.45 and a 52 week high of $36.65. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.45 and a quick ratio of 1.08.

Mallinckrodt (NYSE:MNK) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $1.94 EPS for the quarter, topping the consensus estimate of $1.73 by $0.21. The company had revenue of $791.00 million during the quarter, compared to the consensus estimate of $766.27 million. Mallinckrodt had a negative net margin of 118.53% and a positive return on equity of 14.22%. The company’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.31 EPS. On average, sell-side analysts expect that Mallinckrodt will post 8.4 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Massachusetts Financial Services Co. MA acquired a new stake in Mallinckrodt in the 4th quarter valued at $1,146,000. Comerica Bank grew its position in Mallinckrodt by 2.7% in the 4th quarter. Comerica Bank now owns 55,415 shares of the company’s stock valued at $1,178,000 after purchasing an additional 1,447 shares during the period. GSA Capital Partners LLP acquired a new stake in Mallinckrodt in the 4th quarter valued at $2,524,000. WINTON GROUP Ltd acquired a new stake in Mallinckrodt in the 4th quarter valued at $3,518,000. Finally, Financial Gravity Wealth Inc. acquired a new stake in Mallinckrodt in the 1st quarter valued at $292,000.

Mallinckrodt Company Profile

Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza.

Read More: Special Dividends

Analyst Recommendations for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.